154 Corporate Finance
Glaxo
Ranbaxy
Cipla
Sun
DRL
2001
2000
2001
2000
2001
2000
2001
2000
2001
2000
ProfitabilityEBDIT/total assets
21.81
19.59
13.25
14.3
31.44
30.17
31.42
24.42
33.07
16.9
(percent)
EBIT/total assets
18.11
16.71
11.08
11.98
29.48
28.02
28.39
21.44
27.71
14.61
(percent)
PAT/net worth
14.54
13.39
7.85
8.47
27.06
25.89
32.27
24.29
34.62
16.76
Growth percent(Net) sales growth
18.3
6
23.55
6.92
39.2
18
13.67
32.6
110.3
15
(percent)
Total assets
30.93
11.36
4.63
5.81
31.64
23.57
21.82
8.23
58.09
16.77
Debt (long term)
–45
4.9
–45
196
–7
N.A.
–75.8
N.A.
317
N.A.
Equity (net worth)
42
9.4
–1
3.3
26
N.A.
27
N.A.
20.3
N.A.
PBT
38
0
4.7
–7
35
N.A.
61
N.A.
163
N.A.
PAT
37
–8
–2
–6.8
31.5
N.A.
63
N.A.
140
N.A.
MiscellaneousCurrent assets/
total assets
0.52
0.63
0.59
0.59
0.7
0.69
0.55
0.38
0.56
0.44
No. of shares
74,475,000
59,775,000
115,895,478
115,895,478
59,972,343
46,774,537
46,756,018
76,515,948
31,588,780
Dividend rate
55
50
100
75
45
0
50
0
40
5
(percent)
Price (Rs)
287.7
672.2
1043
538
1272
Exhibit 7.7 contd.